Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Vanda (VM4) Price & Analysis

VM4 Stock Chart & Stats

No data to display
Day’s Range
N/A
52-Week Range
N/A
Previous Close
N/A
Volume
N/A
Average Volume (3M)
N/A
Market Cap
CHF 188.81M
Enterprise Value
CHF 178.36M
Total Cash (Recent Filing)
CHF 140.49M
Total Debt (Recent Filing)
CHF 21.97M
Price to Earnings (P/E)
―
Beta
0.08
Next Earnings
Feb 10, 2027
EPS Estimate
-0.3
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Fanapt Commercial Momentum

Fanapt is showing durable commercial traction, supported by higher sales, prescription growth, and stronger new-to-brand demand. Expansion into bipolar I disorder and broader sales-force coverage can extend the product’s addressable market and help sustain branded revenue over the next several quarters.

Pipeline And Portfolio Expansion

Multiple approved, launch-ready, and late-stage assets give Vanda several avenues to diversify beyond its existing products. BYSANTI’s exclusivity and planned launch, together with NEREUS and Quimilza opportunities, could broaden revenue sources and improve portfolio durability.

Low Balance-Sheet Leverage

Very low leverage provides financial flexibility compared with a debt-heavy pharmaceutical model and reduces the immediate burden of interest and refinancing obligations. This cushion can support commercialization and development spending, although its benefit depends on slowing the company’s ongoing losses and cash consumption.

Bears Say

Elevated Cash Burn

Rapid cash depletion combined with an expectation of higher annual burn creates a meaningful funding and runway risk. Continued investment in launches and clinical programs may require difficult capital-allocation decisions, especially if new products do not scale quickly enough to offset spending.

Severe Profitability Deterioration

The sharp move from near-breakeven results to heavy losses indicates weak current operating leverage and makes revenue growth less valuable until expenses normalize. Persistent losses can erode equity, consume liquidity, and limit Vanda’s ability to fund its broad product and development agenda internally.

HETLIOZ Generic Competition

Generic competition is reducing revenue from a marketed product that remains an important part of the portfolio. Continued volume erosion, with management warning that declines could become significant, may weaken the recurring revenue base and increase reliance on newer products and launches.

Vanda News

VM4 FAQ

What is Vanda’s market cap?
Vanda’s market cap is CHF188.81M.
When is Vanda’s upcoming earnings report date?
Vanda’s upcoming earnings report date is Feb 10, 2027 which is in 101 days.
How were Vanda’s earnings last quarter?
Vanda released its earnings results on Oct 28, 2026. The company reported -CHF0.305 earnings per share for the quarter, beating the consensus estimate of -CHF0.562 by CHF0.257.
Is Vanda overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Vanda pay dividends?
Vanda does not currently pay dividends.
What is Vanda’s EPS estimate?
Vanda’s EPS estimate is -0.30.
How many shares outstanding does Vanda have?
Vanda has 60,469,690 shares outstanding.
What happened to Vanda’s price movement after its last earnings report?
Vanda reported an EPS of -CHF0.305 in its last earnings report, beating expectations of -CHF0.562. Following the earnings report the stock price went same ―.
Which hedge fund is a major shareholder of Vanda?
Currently, no hedge funds are holding shares in CH:VM4
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology